Washington ExaminerLean R·
Peptide exceptionalism is a dangerous FDA loophole. Demand evidence, not hype
The Food and Drug Administration is about to decide whether a scientific word can become a regulatory loophole. On July 23 and 24, the FDA’s Pharmacy Compounding Advisory Committee is scheduled to consider whether several peptides should be added to the list of bulk drug substances that may be used in pharmacy compounding. That sounds […]
Read at Washington Examiner →
